Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBlenheim Natural Resources Regulatory News (BNR)

Share Price Information for Blenheim Natural Resources (BNR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.711773
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.711773
High: 0.00
Low: 0.00
Prev. Close: 0.711773
BNR Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BNR Schedules Earnings Release on August 31, 2023

4 Aug 2023 08:27

RNS Number : 3549I
Burning Rock Biotech Limited
04 August 2023
 

Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023

GUANGZHOU, China, August 4, 2023 - Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2023.

While the Company has not completed the preparation of its financial statements for the second quarter of 2023, it expects to report positive year-over-year and quarter-over-quarter revenue growth in the second quarter, driven by growth of the in-hospital and pharma service business segments. The Company also expects to achieve significant improvement in its base business, where its non-GAAP gross profit has exceeded the non-GAAP SG&A expenses*.

(*) Non-GAAP gross profit refers to gross profit excluding depreciation and amortization. Non-GAAP SG&A refers to selling and marketing expenses and general and administrative expenses, both excluding their respective share-based compensation and depreciation and amortization. We excluded these items primarily because they are non-cash items and are excluded from our internal operating plans and measurement of our financial performance. Non-GAAP gross profit and non-GAAP SG&A are not measurements under accounting principles generally accepted in the United States and may not be similar to non-GAAP measures to other companies. Management believes that these non-GAAP measures are relevant metrics to provide investors more information regarding our financial performance, as these are indicators of our operating performance, especially in a capital-intensive and R&D-focused industry like ours.

 

Please register in advance of the conference using the link provided below and dial in 15 minutes prior to the call, using participant dial-in numbers and unique registrant ID which would be provided upon registering.

PRE-REGISTER LINK:

https://register.vevent.com/register/BI6587397828874b24931eb99fd4fb1c15.

Additionally, a live and archived webcast of the conference call will also be available on the company¡¯s investor relations website at http://ir.brbiotech.com or through link

https://edge.media-server.com/mmc/p/t4sgbsfb.

A replay of the webcast will be available for 12 months via the same link above.

Please visit the Company's investor relations website at https://ir.brbiotech.com/news-events/news-releases on August 31, 2023 to view the earnings release prior to the conference call.

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

 

 

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOREAXPLEFXDEEA
Date   Source Headline
29th Apr 20248:12 amRNSBNR Publishes 2023 Annual Report on Form 20-F
26th Apr 20247:00 amRNSBurning Rock Announces ADS Ratio Change
2nd Apr 20247:00 amRNSBNR Reports 23Q4 and Full Year Financial Results
4th Jan 20247:00 amRNSBNR Announces Receipt of Notification from NASDAQ
20th Dec 20237:00 amRNSBNR Announces Results of 2023 AGM
30th Nov 20237:00 amRNSBNR Reports Third Quarter 2023 Financial Results
22nd Nov 20237:00 amRNSBNR Announces 2023 AGM to be Held on Dec 20, 2023
21st Nov 20237:00 amRNSBNR Schedules Q3 Earnings Release on Nov 30, 2023
30th Oct 20237:09 amRNSBNR and BI Achieved a Master Service Agreement
16th Oct 20237:00 amRNSBNR Received Breakthrough Device Designation
8th Sep 20237:00 amRNSStudy results published in the Cancer Cell
31st Aug 20237:00 amRNSBNR Reports Second Quarter 2023 Financial Results
4th Aug 20238:27 amRNSBNR Schedules Earnings Release on August 31, 2023
28th Jun 20239:04 amRNSAnnounces Resignation and Appointment of Directors
8th Jun 20237:00 amRNSPublished in the New England Journal of Medicine
30th May 20237:00 amRNSBurning Rock Reports 1st Quarter Financial Results
27th Apr 20237:00 amRNSBNR Schedules Q1 Earnings Release on May 30, 2023
21st Apr 20237:00 amRNSBNR Publishes 2022 Annual Report on Form 20-F
28th Mar 20237:00 amRNSBurning Rock Reports Q4 and Full Year 2022 Results
7th Mar 20238:31 amRNSBNR Schedules 22Q4 and Full Year ER on March 28
18th Jan 20237:00 amRNSAn update on 2022 revenue guidance
3rd Jan 20232:53 pmRNSBNR Received FDA Breakthrough Device Designation
16th Nov 20227:00 amRNSBurning Rock Third Quarter 2022 Financial Results
8th Nov 20227:00 amRNSProspectus Supplement Filed with U.S. SEC
1st Nov 20229:54 amRNSAdmission to Trading on the London Stock Exchange

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.